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Abstract
Introduction: Haemoglobin A1c (HbA1c) is considered to be the gold standard for the follow-up of glycaemic control in patients with diabetes melli-
tus and is also a diagnostic tool. Accordingly, reliable and efficient methods must be used for its quantification. Roche Diagnostics have recently 
adapted the Tina-quant® HbA1c Third Generation immunoassay on a fully dedicated analyser, the Cobas c513, which allows a high throughput of up 
to 400 samples per hour. The present article deals with the evaluation of the analytical performances of this system which has been recently intro-
duced to the market.
Materials and methods: Precision, comparison with two ion-exchange high-performance liquid chromatography (HPLC) methods (Variant II and 
D-100 systems, BioRad Laboratories) using Passing Bablok and Bland-Altman analyses, accuracy and interference of the most frequent haemoglobin 
(Hb) variants on HbA1c measurement were evaluated.
Results: Precision was high, with coefficients of variation lower than 1.1% (HbA1c values expressed in National Glycohemoglobin Standardization 
Program units, 1.7% for values expressed in International Federation of Clinical Chemistry and Laboratory Medicine [IFCC] units). The comparison 
study showed similar results with the two HPLC systems. The analysis of samples with IFCC-assigned values showed high methodological accuracy. 
Finally, no interference of bilirubin, triglycerides and common Hb variants (Hb AC, AD, AE, AS) was observed.
Conclusions: This evaluation showed that the analytical performance of the Cobas c513 analyser for HbA1c assay makes it suitable for a routine use 
in clinical chemistry laboratories.
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The term haemoglobin A1c (HbA1c) is commonly 
used to describe the major fraction of glycated 
haemoglobin in blood, which results from the 
non-enzymatic binding of glucose on the N-termi-
nal valine residues of haemoglobin β chains. Hae-
moglobin A1c is considered the best marker for the 
monitoring of diabetic patients because its evalua-
tion provides retrospective information on the gly-
caemic balance of patients for the past 6-8 weeks 
(1). Moreover, elevated HbA1c values are associated 
with the development of long-term complications 
in type 1 and type 2 diabetes (2-4). The number of 
countries recommending the use of HbA1c for the 
diagnosis of diabetes, with a threshold value of 48 
mmol/mol (6.5%), has risen in recent years (5,6). 
The use of HbA1c for such diagnostic purposes re-
quires reliable, accurate, and robust analytical 
methods in order to avoid misdiagnosis, which 
could result in high unwarranted expenditure on 
patient care in the case of over-diagnosis. Conse-
quently, available diagnostic methods must be 
traceable to internationally accepted reference 
methods in order to improve the overall compara-
bility of methods and assessment of their quality 
performance (7,8).
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The evaluation of HbA1c values may be performed 
using a number of methods based on various prin-
ciples, ranging from separative methods (e.g. ion-
exchange chromatography and capillary electro-
phoresis) to immunological assays. Due to both, 
the increasing number of patients with diabetes 
worldwide and the expanded use of HbA1c for dia-
betes diagnosis, the need for HbA1c assessment is 
constantly increasing. To meet these needs, manu-
facturers are now offering robust analytical solu-
tions with higher throughput than previously 
available, particularly in laboratory settings.
Roche Diagnostics have recently adapted the Ti-
na-quant® HbA1c Third Generation immunoassay 
on a fully dedicated analyser, the Cobas c513, 
which allows a sample throughput of up to 400 
samples per hour. The present study was per-
formed to evaluate the analytical performance of 
this system, with a focus on comparison with two 
routine high-performance liquid chromatography 
(HPLC) systems (D-100 and Variant II analysers 
from Bio-Rad Laboratories), the accuracy and pre-
cision of the method, the interference of the most 
frequent haemoglobin (Hb) variants, and the usa-
bility of the system.
Materials and methods
Materials
The analyser and reagents used for this evaluation 
were provided by Roche Diagnostics (Mannheim, 
Germany) and were used according to manufac-
turer’s instructions.
Cobas c513 analyser
Cobas c 513 is a fully dedicated HbA1c assay ana-
lyser with a high throughput, owing the use of 
ready-to-use reagents in a large kit size. This ana-
lyser also makes use of minimized operator inter-
vention; from sample registration to result deliv-
ery, and a closed-tube sampling function. On-
board stability of the reagents is 4 weeks. The ana-
lyser must be calibrated every month or at each 
change of the reagent lot number.
HbA1c determination utilizes the Tina-quant® Third 
Generation assay, which is based on a turbidimetric 
inhibition immunoassay (TINIA) for haemolysed 
whole blood. The first step is the preparation of the 
blood haemolysate using a detergent-containing 
reagent. The second step is the spectrophotomet-
ric measurement of total Hb in the haemolysate, 
converted to a stable derivative at 376 nm. In paral-
lel, HbA1c reacts with the anti-HbA1c antibody to 
form soluble antigen-antibody complexes. Finally, 
the polyhaptens contained in the reagent react 
with excess anti-HbA1c antibodies and form an in-
soluble antibody-polyhapten complex, which is 
measured by turbidimetry at 340 nm (the higher 
the HbA1c concentration, the lower the turbidity). 
The output of this method is linear from 23 mmol/
mol (4.3%) to 196 mmol/mol (20.1%). 
Samples
For the comparison study, blood samples collect-
ed in ethylenediaminetetraacetic acid (EDTA)-con-
taining tubes (Sarstedt, Nümbrecht, Germany) re-
ceived by the Bio-Paris-Ouest laboratory for HbA1c 
measurement, were selected following analysis 
with the D-100 system. Samples were then 
shipped to the Reims University Hospital laborato-
ry at 2-8 °C within the 48 hours, for HbA1c measure-
ment with the Cobas c513 system. 
For the precision study, blood samples were col-
lected in EDTA-containing tubes (BD Vacutainer, 
Le Pont de Claix, France) and sent to the laborato-
ry for routine HbA1c assay. No additional samples 
were necessary for this study, and no samples 
were stored after the assays. Quality control (QC) 
samples (PreciControlA1c Norm and PreciControl-
A1c Path), blood samples with International Feder-
ation of Clinical Chemistry and Laboratory Medi-
cine (IFCC)-assigned values and blood samples 




The precision study was performed according to 
Clinical & Laboratory Standards Institute (CLSI) 
EP05-A3 protocol (9). Quality controls (two levels) 
and patient samples (four levels covering the ana-
lytical range) were analysed in duplicate, twice 
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daily for 21 days (i.e. 84 determinations). Samples 
were aliquoted and stored at - 80 °C to avoid freez-
ing/thawing cycles. The analyser was calibrated 
twice during the precision study and the same re-
agent and calibrator lot numbers were used. The 
acceptance criteria for precision were total impre-
cision coefficients of variation (CVs) lower than 2% 
as recommended in the literature (6).
Comparison study
The comparison study was performed according 
to an internal protocol. For that purpose, samples 
(N = 100) were assayed using Cobas c513 and two 
routinely used HPLC analysers (Variant II equipped 
with a Dual Kit and D-100, Bio-Rad Laboratories, 
Hercules, USA). Haemoglobin A1c values were com-
pared by Passing Bablok regression and Bland-Alt-
man analyses, using samples with HbA1c values 
distributed across the linearity range (10,11). Sam-
ples with Hb variants or elevated values of carba-
mylated Hb (cHb) or labile HbA1c were excluded 
from the comparison study. All comparative assays 
were performed within a 48 hour-period, and 
samples were kept at + 4 °C until analysis. The in-
terpretation of data was based on the results of 
Passing Bablok regression analysis, which allows 
the determination of constant and proportional 
errors, and Bland-Altman analysis in which the 
proportion of outliers had to be lower than 5%.
Accuracy
Eight external assurance quality samples with IFCC-
assigned values obtained from the European Refer-
ence Laboratory for Glycohemoglobin (Winterswi-
jk, The Netherlands) were analysed in triplicate us-
ing the Cobas c513 analyser. Absolute and relative 
biases between the target and the obtained values 
were calculated to evaluate the accuracy of the 
method. The acceptance criteria for accuracy were 
based on those used for the sigma-metrics model 
calculation, in which absolute biases should be 
lower than 5 mmol/mol in IFCC units (12).
Interferences 
The influence of bilirubin and triglycerides on 
HbA1c quantification was studied by mixing washed 
red blood cells with various dilutions of hyperbili-
rubinemic or triglyceride-rich plasmas to obtain 
bilirubin and triglyceride concentrations reaching 
352 μmol/L and 20.6 mmol/L, respectively.
The influence of the most common Hb variants (Hb 
AC, AD, AE, AS) on HbA1c measurement was deter-
mined by analysing samples containing Hb variants 
(N = 10 per variant) with various concentrations of 
HbA1c. Each sample had assigned target values us-
ing a comparison method (IFCC calibrated boronate 
affinity chromatography method, Premier Hb9210) 
which is known to be unaffected by the presence of 
Hb variants (assignment performed at the Europe-
an Reference Laboratory for Glycohemoglobin, The 
Netherlands). In parallel, 40 HbAA samples covering 
the same HbA1c range as variant samples were as-
sayed in order to assess the relative deviation of var-
iant samples compared to normal ones. Haemoglo-
bin AA results were used for the calculation of a re-
gression line, any difference exceeding ± 10% with 
respect to this line in Hb variant samples was con-
sidered clinically significant (13).
Influence of red blood cell sedimentation
In order to determine the impact of red blood cell 
sedimentation on the measurement of HbA1c, ten 
samples were assayed after 1h, 2h, 5h and 24h in-
cubation periods at 4 °C or at room temperature. 
Tubes were not shaken during this incubation time 
so as to not disturb the blood cell sedimentation 
process. After the 24h incubation time, all samples 
were homogenized and analysed again. Values 
were compared with HbA1c values obtained on ag-
itated samples before starting the incubation pe-
riod. The acceptance criteria were based on rela-
tive biases which had to be close to zero and a 
mean relative bias lower than 5%. 
Statistical analyses
Statistics were performed using Graph-Pad Prim 
6.0 and R softwares.
Results
Precision study
For QC samples, the CVs were lower than 1.1% 
when HbA1c values were expressed in % (National 
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Glycohemoglobin Standardization Program 
[NGSP] units) and lower than 1.4% when values 
were expressed in mmol/mol (IFCC units) (Table 1). 
For patient samples, CVs were lower than 1.1% and 
1.7% when HbA1c values were expressed in NGSP 
and in IFCC units, respectively, irrespective of the 
level of HbA1c.
Accuracy
The relative biases ranged from - 0.2% to + 3.4%; 
the mean relative bias was + 1.6% for HbA1c values 
expressed in IFCC units (+ 1.2% for values ex-
pressed in NGSP units) (Table 2). All absolute bias-
es were lower than 3 mmol/mol and the mean ab-
solute bias in IFCC units was + 1.1 mmol/mol (+ 
0.10% HbA1c in NGSP units). 
Comparison study
Haemoglobin A1c values obtained with Cobas c513 
were compared with those obtained with two oth-
er routine analysers: D-100 and Variant II. The com-
parison with D-100 system showed good results, 
with the following linear regression equation: y 
(HbA1c D-100, mmol/mol) = 0.96 x (HbA1c Cobas 
c513, mmol/mol) + 2.54, 95% confidence intervals 
being comprised between 0.94 and 0.97 for slope 
and 1.49 and 3.42 for intercept (Figure 1A). These 
results indicated slight constant and proportional 
errors. The Bland-Altman plot showed a mean dif-
ference equal to - 0.08 ± 1.63 mmol/mol with 5% 
of outliers (i.e. differences outside the range mean 
± 2SD) (Figure 1C). 
Similar results were obtained when Cobas c513 
was compared with Variant II analyser (Figure 1B 
and 1D). In this case, the equation of the regres-
sion line was: y (HbA1c Variant II, mmol/mol) = 1.00 
× (HbA1c Cobas c513, mmol/mol) + 1.57; (95% CI for 
slope = 0.99 - 1.02 and for intercept = 0.72 - 2.50, 
indicating a slight constant error). The Bland-Alt-
man plot showed a mean difference equal to - 1.75 
± 1.12 mmol/mol with 2% of outliers.
For these two comparison studies, the cusum test 
for linearity indicated no significant deviation (P > 
Coefficients of variation (%)
Sample Mean value Repeatability Between-run Between-day Intermediate precision (total)
HbA1c, %
Sample 1 5.8 0.5 0.6 0.8 1.1
Sample 2 6.1 0.7 0.6 0.7 1.1
Sample 3 7.9 0.5 0.8 0.6 1.1
Sample 4 11.6 0.6 0.6 0.7 1.1
QC sample (low-level) 5.7 0.6 0.5 0.4 0.84
QC sample (high-level) 11.1 0.5 0.2 0.9 1.1
HbA1c, mmol/mol
Sample 1 39.9 0.7 1.0 1.2 1.7
Sample 2 42.9 1.0 1.0 1.0 1.7
Sample 3 62.9 0.7 1.1 0.9 1.6
Sample 4 103.5 0.8 0.8 0.9 1.4
QC sample (low-level) 39.2 0.9 0.7 0.7 1.3
QC sample (high-level) 98.2 0.7 0.3 1.1 1.4
Acceptance criteria: the analytical goals usually admitted for precision performances of HbA1c methods are intermediate precision 
CVs lower than 2% (6). HbA1c - haemoglobin A1c. QC - quality control.
Table 1. Results of the precision study on the Cobas c513 
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HbA1c, mmol/mol
EAQ sample IFCC target value Measured value Absolute bias (mmol/mol) Relative bias (%)
Sample 1 31.4 32.1 + 0.7 + 2.2
Sample 2 38.7 38.9 + 0.2 + 0.5
Sample 3 49.6 49.5 - 0.1 - 0.2
Sample 4 58.5 59.3 + 0.8 + 1.2
Sample 5 69.0 69.8 + 0.8 + 1.2
Sample 6 78.3 80.6 + 2.3 + 2.9
Sample 7 88.6 91.6 + 3.0 + 3.4
Sample 8 99.2 100.4 + 1.2 + 1.2
Mean + 1.1 + 1.6
HbA1c, %
Sample 1 5.0 5.1 + 0.07 + 1.5
Sample 2 5.7 5.7 + 0.02 + 0.3
Sample 3 6.7 6.7 - 0.01 - 0.1
Sample 4 7.5 7.6 + 0.08 + 1.0
Sample 5 8.4 8.5 + 0.07 + 0.9
Sample 6 9.3 9.5 + 0.21 + 2.3
Sample 7 10.3 10.5 + 0.27 + 2.6
Sample 8 11.2 11.3 + 0.11 + 0.9
Mean + 0.10 + 1.2
EAQ - external assurance quality. The measured value represents the mean of three HbA1c determinations. The acceptance 
criterion for the evaluation of accuracy is absolute biases lower than 5 mmol/mol in IFCC units (12). HbA1c - haemoglobin A1c. 
IFCC - International Federation of Clinical Chemistry and Laboratory Medicine.
Table 2. Comparison of HbA1c results obtained using Cobas c513 on eight external assurance quality samples with IFCC-assigned 
values
0.2) and residual plots presented distribution of 
differences around fitted regression line without 
systematic deviation (data not shown).
Interferences
No analytical interferences of bilirubin and triglyc-
erides were noted for concentrations reaching 352 
μmol/L and 20.6 mmol/L, respectively (Table 3). 
The relative biases, calculated from HbA1c values 
expressed in mmol/mol, ranged from - 1.4% to + 
1.6% for bilirubin, and between - 4.0% to + 0.8% 
for triglycerides.
For testing the interference of Hb variants, ten 
blood samples containing the most frequent vari-
ants in their heterozygous forms (Hb AC, AD, AE, 
AS) were analysed using Cobas c513. HbA1c values 
were compared with assigned values obtained 
with a boronate affinity chromatography method, 
which is recognized to not be affected by the pres-
ence of Hb variants. First, the two methods were 
compared using 40 HbAA samples which were 
used to establish a linear regression line around 
which an interval of ± 10% was defined (Figure 2). 
Haemoglobin variants were considered to cause 
interference when most of the samples showed 
HbA1c values outside this range. All tested samples 
showed values inside this range, regardless of the 
Hb variant tested, thus, effectively demonstrating 
the absence of interference of these Hb variants 
on HbA1c measurement by the Cobas c513 analys-
er.
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Bilirubin (µmol/L) HbA1c Level 1 (mmol/mol) Relative bias (%) HbA1c Level 2 (mmol/mol) Relative bias (%)
- 36.0 - 62.4 -
88 36.1 + 0.3 63.4 + 1.6
176 36.0 0.0 63.2 + 1.3
264 35.9 - 0.3 63.1 + 1.1
352 35.5 - 1.4 62.3 - 0.2
Triglycerides (mmol/L)
- 37.7 - 60.4 -
5.2 37.7 0.0 60.7 + 0.5
10.3 37.6 - 0.3 60.9 + 0.8
15.5 37.3 - 1.1 59.4 - 1.7
20.6 36.2 - 4.0 59.3 - 1.8
Each value represents the mean of two HbA1c determinations. HbA1c - haemoglobin A1c.
Figure 1. Comparison of HbA1c values obtained with Cobas c513 and D-100TM or VariantTM II systems (N = 100). The methods have 
been compared using Passing-Bablock regression (A and B) and Bland-Altman analyses (C and D). HbA1c - haemoglobin A1c.
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Influence of red blood cell sedimentation
The influence of blood cell sedimentation was 
evaluated by analysing several samples over a 24h 
sedimentation period. At each time point, the 
mean relative biases were calculated using the val-
ues obtained at time zero as a reference. The re-
sults shown in Figure 3 demonstrate that the rela-
tive biases did not exceed 5%. The biases were less 
important when samples have been stored at 4 °C 
instead of room temperature. The biases were 
close to 0% when the samples were agitated 
shortly before analysis at the end of the sedimen-
tation time.
Usability and ergonomics
The Cobas c513 has a high throughput of up to 
400 tests per hour on whole blood samples. It al-
lows closed-tube sampling and offers the possibil-
ity to work on 10 µL whole blood-capillary straws, 
which are loaded and remain in the Sarstedt Tina-
quant tubes containing 1000 µL of haemolysate. 
The system requires minimal daily manual mainte-
nance. Moreover, automatic maintenance may be 
launched during scheduled instrument wake-up, 
allowing a quicker start-up time. No breakdowns 
occurred during the evaluation and the availability 
of tele-maintenance provided training and sup-
Figure 2. Interference of the most frequent Hb variants. HbA1c values obtained with Cobas c513 analyser for patient samples (N = 10) 
containing Hb AC, AD, AE or AS variants were compared with HbA1c values obtained by an IFCC-calibrated boronate affinity chroma-
tography method (Premier Hb9210), which is considered a valuable comparison method for the determination of HbA1c in the pres-
ence of Hb variants. In each case, the solid grey line represents the regression line calculated using Cobas c513 and Premier Hb9210 
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Figure 3. Effect of blood cell sedimentation on HbA1c quantification by Cobas c513.
Blood samples (N = 10) were analysed at t0 and then after 1h, 2h, 5h and 24h of sedimentation either at room temperature or at 4°C. 
At the 24h-sedimentation time, the samples were then agitated and reanalysed (condition 24h*). At each time, the HbA1c values were 
compared with the values obtained at t0 in order to calculate the relative biases, which are represented as box plots. HbA1c - haemo-
globin A1c.
port on the instrument. Other advantages of this 
instrument are the availability of automatic identi-
fication of tube size and caps, labelling of reagent 
cassettes by radio-frequency identification, and 
automatic download of information such as cali-
brator and QC values, which reduces the need for 
manual entries.
Discussion
Haemoglobin A1c is an essential biomarker for 
monitoring the glycaemic status of patients with 
diabetes mellitus and is becoming increasingly 
used for diabetes diagnosis. Its use as a diagnostic 
tool requires the use of reliable, accurate, and ro-
bust analytical methods to avoid misdiagnosis and 
associated healthcare complications. Fortunately, 
important advances have emerged in recent years 
regarding HbA1c assessment, in particular through 
the global standardization of HbA1c assays and the 
development of more systematic external quality 
assurance schemes driven by the IFCC working 
group and the task force for HbA1c standardization 
(14). This process has improved the homogeneity 
of HbA1c assessment and reduced the imprecision 
of the associated methods, thus improving their 
reliability and in turn facilitating the use of HbA1c 
for the screening of subjects with diabetes. All 
methods newly introduced to the market must 
now be traceable and linked to the IFCC reference 
method (7).
The ever-increasing number of patients with dia-
betes worldwide is associated with a greater re-
quirement for HbA1c assays. To meet this demand, 
manufacturers have focused on optimizing their 
analytical systems in recent years to develop high 
throughput solutions that retain the technical per-
formances required for reliable HbA1c determina-
tion. To this end, Roche Diagnostics have recently 
developed a new system, the Cobas c513 analyser, 
which meets the aforementioned criteria and for 
which the Tina-quant® Third Generation immuno-
assay has been adapted. 
Precision studies of this system yielded promising 
results, whereby total imprecision CVs did not ex-
ceed 1.1% in NGSP units and 1.7% in IFCC units, 
consistent with the current recommendations for 
such systems (6,8). As widely acknowledged in the 
literature, CVs calculated from values expressed in 
IFCC units are higher than those obtained from 
NGSP units (15).
The evaluation of accuracy based on the use of 
samples with IFCC-assigned values showed a 
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mean relative bias of + 1.6% and absolute biases 
lower than 5 mmol/mol demonstrating a good 
traceability of this method to the IFCC reference 
system (12). The Cobas c513 analyser was com-
pared with two routine HPLC systems based on 
the same chromatographic separation principles, 
comprising an older system with limited through-
put (Variant II, dual kit, BioRad Laboratories) and a 
more recent system (D-100 system, BioRad Labo-
ratories) (16). The comparison study showed that 
both methods were in good agreement with Co-
bas c513 even though slight proportional and con-
stant errors were found. Moreover, better results 
were obtained with Variant II system.
We did not observe any significant effect of high 
concentrations of bilirubin and triglycerides on 
HbA1c measurement by Cobas c513. Similarly, the 
presence of the most frequent Hb variants did not 
significantly modify the observed values, indicat-
ing that this method is suitable for HbA1c quantifi-
cation even in the presence of such variants. We 
did not assess the impact of labile HbA1c or cHb in 
this study because, unlike separative methods, im-
munoassays are generally not affected by these 
Hb fractions.
Since the analyser does not stir tubes before sam-
pling, we also evaluated the influence of red blood 
cell sedimentation on the HbA1c assay. The sedi-
mentation test showed that, over a 24h period, 
HbA1c values remained close to initial values, with 
relative biases of less than 5%. However, when this 
test was carried out on tubes kept at 4°C between 
each measurement, the biases were even lower 
and came close to zero when the tubes had been 
shaken after 24h of sedimentation. These results 
suggest that, even if these differences are not sig-
nificant, it is advisable to shake the tubes before 
loading them on the device.
The results of this evaluation are consistent with 
two other recently published studies, which 
showed that the Cobas c513 method was compa-
rable to other HbA1c methods and demonstrated 
that it fulfilled the criteria for becoming a second-
ary reference measurement procedure (13,17).
This study has some limitations. For example, the 
comparison study was carried out using two HPLC 
systems with similar methodological principles. A 
comparison with other types of HbA1c assays (e.g. 
capillary electrophoresis or an enzymatic method) 
could further improve our understanding, al-
though such comparisons have already been de-
scribed by other authors (13,17). A further limita-
tion of the present study is that the interference of 
Hb variants would ideally be analysed in a larger 
number of samples.
In conclusion, the Cobas c513 analyser exhibits 
good analytical performance for the measure-
ment of HbA1c at high throughput, making it a reli-
able system for routine practice in clinical chemis-
try laboratories performing large-scale HbA1c as-
says.  
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